Insider Transactions in Q2 2025 at Incyte Corp (INCY)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2025
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
984
+0.01%
|
-
|
|
Jun 30
2025
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
361
+1.55%
|
$24,548
$68.1 P/Share
|
|
Jun 30
2025
|
Mohamed Khairie Issa EVP, Head of US Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
27,812
+26.67%
|
-
|
|
Jun 30
2025
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
367
+1.77%
|
$24,956
$68.1 P/Share
|
|
Jun 26
2025
|
Herve Hoppenot Special Advisor to the CEO |
BUY
Grant, award, or other acquisition
|
Direct |
6,016
+1.05%
|
-
|
|
Jun 10
2025
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,518
+10.78%
|
-
|
|
Jun 10
2025
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,518
+11.53%
|
-
|
|
Jun 10
2025
|
Otis W Brawley Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,518
+18.29%
|
-
|
|
Jun 10
2025
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,518
+11.21%
|
-
|
|
Jun 10
2025
|
Susanne Schaffert Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,518
+25.42%
|
-
|
|
Jun 10
2025
|
Susanne Schaffert Director |
SELL
Payment of exercise price or tax liability
|
Direct |
849
-14.84%
|
$59,430
$70.07 P/Share
|
|
Jun 10
2025
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,518
+10.03%
|
-
|
|
Jun 10
2025
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
5,036
+0.05%
|
-
|
|
Jun 10
2025
|
Katherine A High Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,518
+15.88%
|
-
|
|
Jun 03
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
1,795
-6.34%
|
$122,060
$68.0 P/Share
|
|
Jun 03
2025
|
Sheila A. Denton EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,795
+5.96%
|
$104,110
$58.06 P/Share
|
|
Jun 02
2025
|
Thomas Tray Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
651
-2.87%
|
$41,664
$64.88 P/Share
|
|
May 30
2025
|
Thomas Tray Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
963
-4.08%
|
$62,595
$65.71 P/Share
|
|
Apr 01
2025
|
Paula J Swain EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
22,141
+9.83%
|
-
|
|
Apr 01
2025
|
Steven H Stein EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,165
+20.33%
|
-
|
|
Apr 01
2025
|
Christiana Stamoulis EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,568
+13.63%
|
-
|
|
Apr 01
2025
|
Michael James Morrissey EVP, Head of Tech. Operations |
BUY
Grant, award, or other acquisition
|
Direct |
4,649
+5.12%
|
-
|
|
Apr 01
2025
|
Vijay K Iyengar EVP, GMAPPS |
BUY
Grant, award, or other acquisition
|
Direct |
22,141
+19.14%
|
-
|
|
Apr 01
2025
|
Barry P Flannelly EVP & General Manager US |
BUY
Grant, award, or other acquisition
|
Direct |
26,135
+20.01%
|
-
|
|
Apr 01
2025
|
Herve Hoppenot Special Advisor to the CEO |
BUY
Grant, award, or other acquisition
|
Direct |
66,899
+10.61%
|
-
|